Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) —

SAN DIEGO, August 8, 2019 — Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical needs, today announced financial results for the second quarter, which ended June 30, 2019, and provided a business update.